CompletedPhase 3ACTRN12621000841875

Topical magnesium oil for the treatment of neuropathic symptoms in stage IV and V chronic kidney disease

Sponsor

Royal Prince Alfred Hospital

Enrollment

20 participants

Start Date

Jan 18, 2022

Study Type

Interventional

Conditions

Stage IV/V Chronic Kidney Disease Peripheral Neuropathy

Summary

Neuropathic pain and symptoms are chronic debilitating problems that commonly affect people with advanced kidney disease. Most currently available treatments are taken orally, and may be associated with significant side effects. Also, people with advanced kidney disease are on many medications, and adding additional medications increases the risk of drug interactions. Topical magnesium may represent an alternative treatment for these bothersome symptoms and due to local application, the risk of side effects and drug interactions may be lower. The objective of this study is to determine the effectiveness of daily application of topical magnesium oil for the treatment of neuropathic symptoms (pain, numbness, cramping) in people with stage IV or V chronic kidney disease. The study will also examine the impact of using magnesium oil on quality of life, blood magnesium concentrations and any adverse effects from using magnesium oil. This study will run for a period of 12 weeks, with follow up scheduled every 4 weeks.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria3

Stage IV or V chronic kidney disease (estimated GFR < 30 mL/min) referred to Renal Supportive Care Service at Royal Prince Alfred Hospital.
Symptoms of neuropathy (pain, paraesthesia, cramping)
No contraindication to use of topical magnesium oil (e.g. pre-existing skin condition which may be exacerbated)

Exclusion Criteria3

Inability to provide informed consent (e.g. cognitive impairment)
Inability to read/speak/understand English
Baseline serum magnesium concentration greater than 1.10 mmol/L.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Transdermal Magnesium applied topically to any or all limbs. Volume applied topically: 1 mL to each effected limb (max 4 limbs) daily for 12 weeks. Dose of magnesium: 1 mL contains 144 mg of magnes

Transdermal Magnesium applied topically to any or all limbs. Volume applied topically: 1 mL to each effected limb (max 4 limbs) daily for 12 weeks. Dose of magnesium: 1 mL contains 144 mg of magnesium chloride. Compliance will be monitored using a daily compliance form, on which, participants will be asked to record whether on not the intervention was used on any given day. The compliance form will be reviewed every follow up appointment.